Details for Patent: 10,912,781

Which drugs does patent 10,912,781 protect, and when does it expire?

Patent 10,912,781 protects APTIOM and is included in one NDA.

This patent has thirty-three patent family members in twenty-two countries.

Summary for Patent: 10,912,781

Title:	Pharmaceutical composition comprising licarbazepine acetate
Abstract:	A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition.
Inventor(s):	Teöfilo Cardoso de Vasconcelos, Ricardo Jorge dos Santos Lima, Rui Cerdeira de Campos Costa
Assignee:	Bial Portela and Cia SA
Application Number:	US15/397,945
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,912,781
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Process; Device; Dosage form;

Drugs Protected by US Patent 10,912,781

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-001	Nov 8, 2013	AB	RX	Yes	No			Y
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-002	Nov 8, 2013	AB	RX	Yes	No			Y
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-003	Nov 8, 2013	AB	RX	Yes	No			Y

International Family Members for US Patent 10,912,781

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2214636		C02214636/01	Switzerland
Argentina	069031
Australia	2008317584